Navigation Links
Myoscience Announces the Completion of Enrollment in the Campbell Clinic Study
Date:10/31/2018

Myoscience, Inc. announced today that it has completed enrollment in its randomized, controlled trial at the Campbell Clinic in Memphis, Tennessee. This study enrolled 125 patients and compares the effect of cryoanalgesia using the iovera° system to the standard of care for managing pain after total knee replacement surgery (TKA).

The Myoscience iovera° system is currently being used to treat chronic and perioperative knee pain. The Campbell Clinic study will demonstrate how cryoanalgesia can significantly reduce opioid consumption after TKA, and lead to improved physical function and enhanced recovery. Analysis of interim data confirms that cryoanalgesia with the iovera° system can be a preferred treatment for relieving postoperative TKA pain.

“I am very impressed with the results of this prospective randomized study thus far. The positive effect of the iovera° system has exceeded our original expectations”, stated Dr. William Mihalko, MD, Principal Investigator for this study. “Having a technology as effective as this to combat excessive opioid use after primary TKA can be a game changer for many patients. Many of us will adopt the use of the technology on a regular basis at my institution,” he added.

The company will be sharing these interim results during a sponsored symposium at the upcoming American Association of Hip and Knee Surgeons (AAHKS) annual meeting in Dallas, Texas. The symposium “Cryoanalgesia: A Path to an Opioid-Free TKA, Pre-op through Rehab,” will be held from 10 a.m. to noon on November 1.

Timothy I. Still, President and CEO of Myoscience stated, “I share Dr. Mihalko’s enthusiasm about iovera°. We look forward to sharing these interim results during the AAHKS meeting in a few days.”

For additional information, please visit http://www.iovera.com or email us directly at mediarelations(at)myoscience(dot)com.

ABOUT MYOSCIENCE
Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by a patented device that enables cryoneurolysis. The ioveraº system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit http://www.iovera.com.

© 2018 Myoscience. All rights reserved. iovera° is a trademark of Myoscience. MKT-0524 REV A

Read the full story at https://www.prweb.com/releases/myoscience_announces_the_completion_of_enrollment_in_the_campbell_clinic_study/prweb15878597.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Molecular Devices Announces Brand Identity for Its Newly-Formed Biologics Business Unit
2. AMIA Announces 2018 Signature Award and Leadership Award Recipients
3. Voxx Analytics Announces Release of Voxx.Gateway for Medical Device and Early-Stage Life Science Companies
4. GlycoMark®, Inc. Announces Partnership with Premier Medical Laboratory Services to Expand Diabetes Test Menu
5. LabRoots Announces Winner for the Second Annual Summer Textbook Scholarship
6. NanoScientific Symposium on SPM at SUNY Polytechnic Announces Registration for Live Stream of Event Sept. 19, 2018
7. Nanovis Announces Successful Completion of $5.5 Million Investment Round To Fund Technology-Driven Growth
8. The Freedom from Cancer Startup Challenge Announces Companies Advancing 100+ Cancer Inventions
9. SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial
10. NanoValent Pharmaceuticals Announces Exclusive Global Licensing Agreement with Children’s Hospital Los Angeles and Completion of First Wave of Financing
11. Pittcon Announces 2018 Award Recipients for Outstanding Achievements in Analytical Chemistry and Applied Spectroscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2019)... ... January 04, 2019 , ... Triangle Insights Group, a premier ... Ted will be joining the firm as a partner. , Ted has ... the pharmaceutical industry. At Triangle Insights, Ted will apply his deep expertise in ...
(Date:1/4/2019)... DIEGO (PRWEB) , ... January 03, 2019 , ... ... at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the founding ... Biotherapeutics to receive critical input and guidance from key leaders in the Immuno-Oncology ...
(Date:12/19/2018)... FREDERICK, Md. (PRWEB) , ... December 19, 2018 ... ... solutions for Life Science, announces the validated release of Limfinity® version 7.1. The ... another important technical offering from RURO as 2018 comes to an end. , ...
(Date:12/18/2018)... ... 18, 2018 , ... Patients with early stages of breast cancer who undergo ... versus whole breast irradiation, a new study suggests. , Patients with early stage breast ... after removal of the cancerous tumor because there is a 30 to 40 percent ...
Breaking Biology Technology:
(Date:1/10/2019)... (PRWEB) , ... January 09, 2019 , ... Dr. Beanlands ... Heart Institute in Ottawa, Ontario, Canada. He is also Director of its National ... of Medicine, in the Department of Radiology, and in the Department of Cellular and ...
(Date:1/8/2019)... ... January 07, 2019 , ... Join industry experts Julie Peacock, Client Services at ... on Thursday, January 17, 2019 at 1pm EST. , This webinar will ... clinical trial process. Featured speakers will also present a case study of a leading ...
(Date:1/7/2019)... (PRWEB) , ... January 07, 2019 , ... ... (RWD) and Artificial Intelligence solutions for precision health in oncology and other key ... J.P Morgan’s exclusive meeting of investors, entrepreneurs and executives spanning the entire healthcare ...
Breaking Biology News(10 mins):